Cooper Companies, Inc.: Form 10-Q for the period ended Jul 31, 2026
Filed with the SEC on Sep 9, 2026 and accepted by EDGAR at Sep 9, 2026, 16:48 ET.
Management's discussion and analysis
As filed, 1,193 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
In September 2025, the authorization under the 2012 Share Repurchase Program was increased to $2.0 billion by the Company's Board of Directors. As of July 31, 2026, $521.7 million remains authorized for repurchase.
In September 2026, the Company's Board of Directors approved an increase of $1.0 billion under the Company's 2012 Share Repurchase Program, increasing the total authorization to $3.0 billion. As of the date of approval, approximately $1.5 billion remains authorized for repurchase.
The following table provides information about the shares repurchased by the Company for the three months ended July 31, 2026:
| Period | Total number of shares purchased (in thousands) | Average price paid per share | Total number of shares purchased as part of publicly announced plan (in thousands) | Approximate dollar value of shares that may yet be purchased under the plan (in millions) |
|---|---|---|---|---|
| May 1, 2026 to May 31, 2026 | — | $— | — | $860.8 |
| June 1, 2026 to June 30, 2026 | 3,412.8 | 67.79 | 3,412.8 | 629.4 |
| July 1, 2026 to July 31, 2026 | 1,489.3 | 72.30 | 1,489.3 | 521.7 |
| Total | 4,902.1 | $69.16 | 4,902.1 | $521.7 |
Market risk
As filed, 2,449 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
We are exposed to market risks that relate principally to changes in interest rates and foreign currency fluctuations. We do not enter into derivative financial instrument transactions for speculative purposes.
Foreign Currency Exchange Risk
We operate multiple foreign subsidiaries that manufacture and market our products worldwide. As a result, our earnings, cash flow and financial position are exposed to foreign currency risk from foreign currency denominated receivables and payables, sales transactions, capital expenditures and net investment in certain foreign operations. Most of our operations outside the United States have their local currency as their functional currency. We have exposure to multiple foreign currencies, including, among others, the British pound, Euro and Japanese yen. We have taken steps to minimize our balance sheet exposure by entering into foreign currency forward contracts to minimize the short-term impact of foreign currency exchange rate fluctuations on certain trade and intercompany receivables and payables.
At July 31, 2026, a uniform hypothetical 10% increase or decrease in the foreign currency exchange rates in comparison to the value of the U.S. dollar would have resulted in a corresponding increase or decrease of approximately $29.5 million in operating income for the fiscal quarter ended July 31, 2026. See Note 11. Financial Derivatives and Hedging of the Consolidated Condensed Financial Statements for further information.
Interest Rate Risk
We are exposed to risks associated with changes in interest rates. Net of interest rate swaps, the majority of our total indebtedness remains subject to US-based variable interest rate risk tied to changes in the federal funds rate and SOFR. We have entered, and in the future may enter, into interest rate swaps to manage interest rate risk.
Our ultimate realized gain or loss with respect to interest rate fluctuations will depend on interest rates, the exposures that arise during the period and our hedging strategies at that time. As an example, if interest rates were to increase or decrease by 1% or 100 basis points, the quarterly interest expense would not have a material impact, based on average debt outstanding, after consideration of our interest rate swap contracts, during the third quarter of fiscal 2026. See Note 4. Financing Arrangements of the Consolidated Condensed Financial Statements for further information.
Controls and procedures
As filed, 1,427 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Evaluation of Disclosure Controls and Procedures
Based on management’s evaluation (with the participation of our Chief Executive Officer (our Principal Executive Officer) and Chief Financial Officer (our Principal Financial Officer)), as of the end of the period covered by this report, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, (the Exchange Act)) are effective as of July 31, 2026 to provide reasonable assurance that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms and is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting
There have been no changes in our internal control over financial reporting identified in connection with the evaluation required by Rules 13a-15(d) and 15d-15(d) of the Exchange Act during our third quarter of fiscal 2026, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Risk factors
As filed, 818 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Our business faces significant risks. These risks include those referenced below and may include additional risks and uncertainties not presently known to us or that we currently deem immaterial. Our business, financial condition and results of operations could be materially adversely affected by any of these risks, and the trading prices of our common stock could decline by virtue of these risks. These risks should be read in conjunction with the other information in this report.
Risk factors describing the major risks to our business can be found under Item 1A. Risk Factors in our Annual Report on Form 10-K for the fiscal year ended October 31, 2025. There have been no material changes to the risk factors previously disclosed in our Annual Report on Form 10-K for the fiscal year ended October 31, 2025.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2026-07-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2026-05-01 to 2026-07-31 | $1.07bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2025-11-01 to 2026-07-31 | $3.17bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2026-05-01 to 2026-07-31 | $354.3m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months2025-11-01 to 2026-07-31 | $1.03bn | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2026-05-01 to 2026-07-31 | $711.9m | us-gaap:GrossProfit |
| Gross profit | 9 months2025-11-01 to 2026-07-31 | $2.14bn | us-gaap:GrossProfit |
| Research and development | 3 months2026-05-01 to 2026-07-31 | $41.6m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2025-11-01 to 2026-07-31 | $128.4m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2026-05-01 to 2026-07-31 | $401.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2025-11-01 to 2026-07-31 | $1.47bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2026-05-01 to 2026-07-31 | $222.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2025-11-01 to 2026-07-31 | $403.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2026-05-01 to 2026-07-31 | $21.5m | us-gaap:InterestExpenseNonoperating |
| Interest expense | 9 months2025-11-01 to 2026-07-31 | $64.8m | us-gaap:InterestExpenseNonoperating |
| Income tax | 3 months2026-05-01 to 2026-07-31 | −$231.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2025-11-01 to 2026-07-31 | −$140.1m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2026-05-01 to 2026-07-31 | $432.8m | us-gaap:NetIncomeLoss |
| Net income | 9 months2025-11-01 to 2026-07-31 | $485.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2026-05-01 to 2026-07-31 | $2.24 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2025-11-01 to 2026-07-31 | $2.49 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2026-05-01 to 2026-07-31 | $2.24 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2025-11-01 to 2026-07-31 | $2.50 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2026-05-01 to 2026-07-31 | 193,400,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2025-11-01 to 2026-07-31 | 195,200,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2025-11-01 to 2026-07-31 | $785.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2025-11-01 to 2026-07-31 | $257.3m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 9 months2025-11-01 to 2026-07-31 | $447.2m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2026-07-31 | $154.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2026-07-31 | $2.28bn | us-gaap:AssetsCurrent |
| Total assets | At period end2026-07-31 | $12.67bn | us-gaap:Assets |
| Current liabilities | At period end2026-07-31 | $1.87bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2026-07-31 | $4.34bn | us-gaap:Liabilities |
| Long-term debt | At period end2026-07-31 | $1.91bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2026-07-31 | $628.1m | us-gaap:DebtCurrent |
| Short-term borrowings | At period end2026-07-31 | $627.5m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | At period end2026-07-31 | $8.33bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001628280-26-061160. Last ingested by Listed: Oct 27, 2026, 16:37 ET. Listed shows no prices and gives no investment advice.